Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00277550
Status:
WITHDRAWN
Last Update Posted:
2016-03-04
First Post:
2006-01-13
Brief Title:
The Effects of Tegaserod vs Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Evaluation of the Effects of Tegaserod 6 mg bid on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia
Status:
WITHDRAWN
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with CC and upper GI symptoms of dyspepsia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None